Aurobindo Pharma is planning to launch 50 to 60 new products in US in FY21. The company has received final approval for six ANDAs (Abbreviated New Drug Application) and launched four products in the fourth quarter of last fiscal. For the full year, it has received approval for 22 ANDAs and launched 34 products across oral, injectable and OTC segments.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
